Acetylon Pharmaceuticals recently published the outcomes of its preclinical data concerning the mechanism of action of its selective inhibition based treatment of sickle cell (SC) disease/beta-thalassemia (BT). These findings, “Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2,” were published in…
News
Recent Posts
- Mount Sinai team to study sickle cell triggers in everyday life
- Raising a child with sickle cell means showing up with purpose
- What I’ve learned about sickle cell-related hospital admissions
- Why I go into overdrive for Sickle Cell Awareness Month every September
- Balancing my education goals with my sickle cell needs